Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28967239 | 0.79 | GSK3A (0.64) | GSK3AGSK3BMEN1KMT2AALDH1A1 | |
| SCHEMBL28786447 | 0.78 | PER2 (0.38) | ALDH1A1HRH3TSHRHTTHCRTR1 | |
| SCHEMBL29672369 | 0.78 | PER2 (0.38) | ALDH1A1HRH3TSHRHTTHCRTR1 | |
| SCHEMBL13548286 | 0.71 | PTGS2 (0.47) | ALDH1A1DAOTSHR | |
| SCHEMBL23343786 | 0.70 | CYP4F2 (0.46) | ALDH1A1DAO | |
| SCHEMBL17205092 | 0.70 | TAAR1 (0.58) | — | |
| SCHEMBL7664052 | 0.69 | CYP4F2 (0.44) | ALDH1A1TSHRROCK2 | |
| SCHEMBL21098761 | 0.68 | FFAR4 (0.51) | POLB | |
| SCHEMBL17525752 | 0.68 | CA1 (0.40) | GSK3AGSK3BALDH1A1DAOHRH3 | |
| SCHEMBL29924049 | 0.67 | CYP19A1 (0.51) | PARK7TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| CN-114727974-A | HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021021979-A2 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281814-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | GSK3A 324/4885GSK3B 312/4885PARK7 72/4885 |
| US-12528767-B2 | HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC11 | GSK3A 174/4885GSK3B 134/4885PARK7 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.